Germany, July 3 -- Germany based Takeda GmbH has secured contract from DAK-Gesundheit for Pharmaceutical Products - Completion of a non -exclusive discount agreement according to Section 130a (8) SGB V for the active ingredient Vedolizumab, ATC L04AA33 for the time 01072023 - 30062025. The value of the contract is not disclosed.
Published by HT Digital Content Services with permission from Pivotal Sources....